Resectable Colon Cancer
Oncology
Prevalence
135.0 / 100K
Incidence
36.0 / 100K/yr
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| Calcium Folinate | Merus N.V. (MRUS) |
Frequently asked questions
How many drugs are in development for Resectable Colon Cancer?
BioSniper tracks 1 drug in development for Resectable Colon Cancer across 1 company.
How many clinical trials target Resectable Colon Cancer?
There are 1 clinical trial targeting Resectable Colon Cancer tracked by BioSniper.
What is the prevalence of Resectable Colon Cancer?
The estimated prevalence of Resectable Colon Cancer is approximately 135.0 per 100,000 population.
Deep-dive into Resectable Colon Cancer
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis